ストックスクリーナーアプリを入手
7.8524
4.94%
-0.4476
前日終値:
$8.30
開ける：
$8.23
24時間の取引高:
702.69K
Relative Volume:
0.26
時価総額：
$359.02M
収益：
$27.10M
当期純損益:
$-24.31M
株価収益率:
-9.4607
EPS:
-0.83
ネットキャッシュフロー:
$-33.33M
1週間 パフォーマンス:
-2.23%
1か月 パフォーマンス:
+6.84%
6か月 パフォーマンス:
-50.53%
1年 パフォーマンス:
+106.54%
1日の値動き範囲:
$7.8101
$8.305
1週間の範囲:
$7.60
$9.43
52週間の値動き範囲:
$3.84
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
名前
Capricor Therapeutics Inc
セクター
電話
(310) 358-3200
住所
10865 ROAD TO THE CURE, SAN DIEGO, CA
CAPR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
7.86 | 367.52M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.55 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
568.05 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
441.57 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
650.00 | 39.02B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
308.53 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-30 | 開始されました | Alliance Global Partners | Buy |
| 2025-06-26 | 開始されました | B. Riley Securities | Buy |
| 2025-05-20 | 開始されました | Roth Capital | Buy |
| 2024-10-21 | 開始されました | Piper Sandler | Overweight |
| 2024-05-17 | 開始されました | Oppenheimer | Outperform |
| 2024-01-05 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-10-26 | 開始されました | Ladenburg Thalmann | Buy |
| 2018-12-26 | ダウングレード | Maxim Group | Buy → Hold |
| 2018-01-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-09-15 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-02-13 | 再開されました | Rodman & Renshaw | Buy |
| 2016-07-06 | 再開されました | H.C. Wainwright | Buy |
| 2016-06-15 | 開始されました | ROTH Capital | Buy |
すべてを表示
Capricor Therapeutics Inc (CAPR) 最新ニュース
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Capricor Therapeutics, Inc.(CAPR) Shareholders - Morningstar
Applying big data sentiment scoring on Capricor Therapeutics Inc.Swing Trade & Weekly Watchlist for Hot Stocks - Newser
Published on: 2025-08-14 06:24:14 - Newser
Capricor Therapeutics, Inc. Securities Fraud Class Action - GlobeNewswire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Capricor - GlobeNewswire
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Capricor Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capricor - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capricor Therapeutics, Inc. – CAPR - FinancialContent
Best data tools to analyze Capricor Therapeutics Inc. stockWeekly Trend Report & AI Driven Stock Price Forecasts - Newser
What does recent volatility data suggest for Capricor Therapeutics Inc.Weekly Gains Report & Free Community Consensus Stock Picks - Newser
Lawsuit Alert: Investors who lost money with shares of Capricor - openPR.com
CAPR Stock News: Investors with Large Losses Should Contact Robbins LLP to Learn About Leading the Capricor Therapeutics, Inc. Class Action Lawsuit - Morningstar
Capricor Therapeutics Inc (CAPR) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP - GlobeNewswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics - FinancialContent
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ACCESS Newswire
Levi & Korsinsky Reminds Capricor Therapeutics, Inc. - GlobeNewswire
Capricor Therapeutics Inc (CAPR) Q2 2025 Earnings Call Highlights: Navigating Challenges with ... - Yahoo Finance
Capricor Therapeutics: Q2 2025 Financial and Strategic Update - TipRanks
Capricor Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Bragar Eagel & Squire, P.C. Urges Investors in XPLR - GlobeNewswire
Bragar Eagel & Squire, P.C. Urges Investors in XPLR Infrastructure, Centene, Biohaven, or Capricor to Inquire About Their Rights in Class Action Lawsuits - GlobeNewswire Inc.
Capricor: Q2 Earnings Snapshot - San Antonio Express-News
Earnings call transcript: Capricor Therapeutics Q2 2025 sees widened loss, stock dips - Investing.com
Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
A mild market reaction for companies on Prasad’s return - BioWorld MedTech
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc.CAPR - PR Newswire
Vinay Prasad’s Return to FDA Sends Biotech Shares Tumbling - Bloomberg.com
Investors in Capricor Therapeutics, Inc. Should Contact The Gross Law Firm Before September 15, 2025 to Discuss Your RightsCAPR - MarketScreener
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - MarketScreener
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Zurcher Kantonalbank Zurich Cantonalbank Purchases 3,162 Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) - Defense World
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Capricor - GlobeNewswire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure - Bluefield Daily Telegraph
Custom watchlist performance reports with Capricor Therapeutics Inc.Monthly Trade Result and Signal Summary - Newser
Analyzing drawdowns of Capricor Therapeutics Inc. with statistical toolsTrade Safety Matrix for Conservative Traders - Newser
What earnings revisions data tells us about Capricor Therapeutics Inc.Value Investing Summary and Earnings Outlook - Newser
Why Capricor Therapeutics Inc. is moving todayVolume Spike Detection for Early Breakouts - Newser
Class Action Filed Against Capricor Therapeutics, Inc. - GlobeNewswire
Capricor stock rises on FDA meeting for rejected drug (CAPR) - Seeking Alpha
Duchenne Muscular Dystrophy Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sarepta Therapeutics, Santhera Pharma, ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeutics - Barchart.com
Capricor schedules FDA meeting on Duchenne therapy, delays earnings By Investing.com - Investing.com Canada
Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA | CAPR Stock News - GuruFocus
Class Action Filed Against Capricor Therapeutics, Inc. (CAPR) Seeking Recovery for InvestorsContact Levi & Korsinsky - PR Newswire
Capricor Therapeutics Schedules FDA Meeting to Discuss Deramiocel BLA for Duchenne Muscular Dystrophy - Quiver Quantitative
Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA - GlobeNewswire
Capricor's DMD Treatment Reaches Critical FDA Milestone: Type A Meeting to Discuss BLA Path - Stock Titan
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Consensus Rating of “Buy” from Analysts - Defense World
Institutional scanner results for Capricor Therapeutics Inc.Risk Aware Swing Trade Analysis Insights - Newser
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Capricor Therapeutics Inc (CAPR) 財務データ
収益
当期純利益
現金流量
EPS
0.26%
0.09%
大文字化:
|
ボリューム (24 時間):